Table 2. Association of HLA-DR15 with... | American Society of Hematology

Table 2.

Association of HLA-DR15 with pretreatment variables in NIH MDS patients

HLA type	Myeloblasts more than 5% in bone marrow^*,^†	Coexistent PNH^*	Abnormal cytogenetics	Hypocellular bone marrow (less than 30% cellularity)	IPSS low risk and intermediate-1	Fewer than 6 mo RBC tx dependence	Age less than 60 y
DR15-negative, %	15	4.4	38.3	21.7	85.1	43.8	37.5
DR15-positive, %	2.0	22.2	17.2	34.5	93.1	44.8	48.3

HLA type	Myeloblasts more than 5% in bone marrow^*,^†	Coexistent PNH^*	Abnormal cytogenetics	Hypocellular bone marrow (less than 30% cellularity)	IPSS low risk and intermediate-1	Fewer than 6 mo RBC tx dependence	Age less than 60 y
DR15-negative, %	15	4.4	38.3	21.7	85.1	43.8	37.5
DR15-positive, %	2.0	22.2	17.2	34.5	93.1	44.8	48.3

RBC tx indicates red blood cell transfusion.

P < .05, χ² test (univariate analysis).

P < .05, logistic regression (multivariate analysis).